Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2009

View Archived Issues

Early clinical data on novel cancer therapeutics disclosed at ASCO

Vertex claims inhibitors of voltage-gated sodium channels

Kyowa Hakko Kirin presents novel glucocorticoid receptor ligands

Bristol-Myers Squibb describes SERT and NK1R antagonists

XenoPort reports results from phase II arbaclofen placarbil trial

Preclinical, phase I and phase II data on BIM-23A760 presented

Meta-analysis finds reduced cardiovascular risk factors with liraglutide treatment

BiovaxID anticancer vaccine now available on a named-patient basis in Europe

Celera licenses five cancer-related targets to Bayer Schering Pharma

New phase I/II data presented on tremelimumab in metastatic melanoma

ADVANCE study shows reduced cardiovascular risk with Preterax in diabetes patients

Nicotinic alpha7 agonist from Arthrogen reduces experimental arthritis severity

Additional preclinical data on AMAP-102 encourage investigation in humans

Adventrx announces plans to submit an NDA for vinorelbine during second half of 2009

CytRx reports results from phase II trial of tamibarotene as third-line treatment for APL

Antitope and Vascular sign research agreement for therapeutic antibodies in vascular disease

Chugai reports results from phase III study of Epogin in chemotherapy-induced anemia

Photocure submits NDA to FDA for Hexvix in detection of papillary bladder cancer

Calixa commences phase II CXA-101 trial for complicated urinary tract infections

Wyeth and Catalyst to develop and commercialize factor VIIa products

Santhera reports results from phase IIb study of fipamezole in PD

European Commission grants marketing authorization for AstraZeneca's Iressa in NSCLC

Momenta reports results from phase II EMINENCE trial of M-118 in CAD

UCB and Biogen discontinue phase II clinical trial of CDP-323 in multiple sclerosis

European CHMP recommends marketing authorization for Tigenix's ChondroCelect

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 16, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...